Loading…
Hosted by ImagicaHealth · 🇺🇸 US · EN · 21 episodes
Established thought leaders with verified media credentials.
Want to stay updated with the latest in diabetes research, reviews, and perspectives? Our content is curated, written, and edited by practicing healthcare professionals with clinical and scientific expertise in diabetes care.Our editorial team is comprised of highly-trained physicians. Our summaries are designed to deliver concise, relevant insights to support effective diabetes management in clinical practice. New summaries are available monthly.
ImagicaHealth hosts AjaDuo Update Podcast- Diabetes News & Clinical Updates, a health show with 21 episodes published.
Abstract The latest Type 2 Diabetes Mellitus (T2DM) management guidelines from the UK National Institute for Health and CareExcellence (NICE; NG28) have raised the profile of sodium-glucose cotransporter-2 inhibitors (SG
Abstract Although sodium–glucose co-transporter-2 (SGLT2) inhibitorsprovide cardiorenal benefits, direct comparisons between dapagliflozin and empagliflozin—the two most commonly used and studied agents in this class—rem
Abstract Aims Adequate cardiovascular risk control prevents complications. A multifactorial approach for simultaneously managing risk factors is recommended by guidelines. We evaluated cardiovascular risk factors among D
Abstract Objective: While glycemic control reduces the progression of diabetic retinopathy (DR), the effects of specific glucose-lowering drugs (GLD) remain incompletely defined. Emerging evidence suggests that sodium-gl
Abstarct: Introduction and Objective: Early-onset type 2 diabetes (T2D) is associated with a more adverse cardiometabolic profile and increased cardiovascular (CV) risk. We aimed to characterize cardiovascular risk and s
Abstarct: Introduction and Objective: Glucagon-like peptide-1 receptor agonists (GLP-1RA) and Sodium-glucose transporter 2 inhibitors (SGLT2i) are crucial components of type 2 diabetes care, especially for adults with Ca
Abstarct: Introduction and Objective: Despite cardiovascular benefits of Sodium-glucose cotransporter 2 inhibitors (SGLT2i), treatment persistence is suboptimal in routine clinical practice. We investigated whether longe
Abstarct: Introduction and Objective: We previously showed that Sodium–Glucose Cotransporter 2 Inhibitors (SGLT2 inhibitors) stimulate endogenous glucose production, offsetting their glucosuria-induced glucose lowering a
Objective: Over 99% of the EMPA-REG OUTCOME trial participants had established cardiovascular disease (CVD). We aimed to investigate effectiveness and safety outcomes among patients with type 2 diabetes (T2D) initiating
Introduction: Diabetes mellitus (DM) is a chronic metabolic disorder marked by persistent hyperglycemia. While HbA1c has traditionally been used to assess glycemic control, growing evidence highlights glycemic variabilit
Background: Sodium-glucose cotransporter (SGLT) 2 inhibitors attenuate fasting glomerular hyperfiltration in people with type 2 diabetes (T2D). However, Sodium-glucosecotransporter 2-inhibition increases glucagon levels,
Introduction: Diabetes mellitus is a chronic condition that requires consistent self management to prevent complications and maintain quality of life. This meta-analysis estimated the pooled prevalence of various self-ca
Objective: This study aimed to compare the effects of empagliflozin-metformin versus empagliflozin- linagliptin combination therapy on cardiovascular parameters and anemia in patients with type 2 diabetes mellitus (T2DM)
Background: Diabetics with coronavirus disease 2019 (COVID-19) manifest more adverse clinical outcomes with elevated rates of death. It has been suggested that the SARS-CoV-2 (severe acute respiratory syndrome coronaviru
Introdution: Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD) are highly interconnected, impacting global health. Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i)and Glucagon-Like Peptide-1 Receptor Ago
Background: Diabetes is a major public health concern in India, contributing significantly to morbidity and mortality. With variations in disease burden across states, a detailed understanding of trends in incidence, pre
Abstract Background: Mounting evidence indicates that Type 2 diabetes mellitus (T2DM) is a public healthchallenge globally, and its occurrence is anticipated to surge in the forthcoming years. Dipeptidyl peptidase‐4 (DPP
Abstract Aims: Guidelines for type 2 diabetes recommend add-on agents when metformin alone fails to provide adequate glycaemic control. However, early combination therapy may benefit health outcomes. We conducted a syste
Abstract Importance: Sodium-glucose cotransporter 2 (SGLT2) inhibitors favorably affect cardiovascular (CV) and kidney outcomes; however, the consistency of outcomes across the class remains uncertain. Objective: To perf
Abstract Introduction and Objective: To analyze the efficacy, safety and tolerability of SGLT2i and DPP-4i combination vs placebo as add-on or initial therapy in Asian patients with T2DM as available data is heterogenous
Sponsor detection runs nightly. Check back soon.
No public pitch examples yet for this show.
Generate your own personalised pitchBased on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
AjaDuo Update Podcast- Diabetes News & Clinical Updates has a verified contact on file. Create a free PitchCentric account to access it and generate a personalised pitch in seconds. Research at least 3 recent episodes first and lead with a specific angle that serves their health audience.
AjaDuo Update Podcast- Diabetes News & Clinical Updates is hosted by ImagicaHealth. The show is categorised under health (fitness) and has published 21 episodes.
AjaDuo Update Podcast- Diabetes News & Clinical Updates has published 21 episodes.
AjaDuo Update Podcast- Diabetes News & Clinical Updates regularly covers health, fitness. It sits in the health category, with a fitness focus.
AjaDuo Update Podcast- Diabetes News & Clinical Updates is accessible for guests with genuine health expertise. A personalised, episode-aware pitch will still outperform a generic one every time.
AjaDuo Update Podcast- Diabetes News & Clinical Updates hasn't explicitly signalled guest openness in recent episodes. That doesn't rule out pitching. your hook just needs to be especially compelling and relevant to their recent content.
Episodes of AjaDuo Update Podcast- Diabetes News & Clinical Updates average 3 minutes. a focused format where a clear narrative arc and tight preparation matter most.
Our data rates AjaDuo Update Podcast- Diabetes News & Clinical Updates's guest bar at 80/100 (Premium tier). Established thought leaders with verified media credentials. Sign in to PitchCentric to see how your own Pod Score compares against this show.
Methodology. Booking Probability™ blends Listen Score, 30-day Virality, open-to-guests detection, and Apple ratings. Data refreshed every 60 minutes. Listen Score and Booking Probability are calculated by PitchCentric. Last enriched 5 days ago.